Loading…
Adicet Bio, Inc. is projected to rise to $9.52 by 2027, a +8% move from its current price of $8.83. ACET is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $8.53 | $8.83 | $9.13 | -0.03% |
| Jul 14 | $8.41 | $8.82 | $9.26 | -0.06% |
| Jul 15 | $8.31 | $8.82 | $9.36 | -0.10% |
| Jul 16 | $8.24 | $8.82 | $9.44 | -0.13% |
| Jul 17 | $8.17 | $8.82 | $9.52 | -0.16% |
| Jul 18 | $8.10 | $8.81 | $9.58 | -0.19% |
| Jul 19 | $8.05 | $8.81 | $9.65 | -0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.05 | $8.81 | $9.65 | -0.22% |
| Week 2 | $7.73 | $8.79 | $9.99 | -0.45% |
| Week 3 | $7.50 | $8.77 | $10.26 | -0.67% |
| Week 4 | $7.30 | $8.75 | $10.49 | -0.89% |
| Week 5 | $7.13 | $8.73 | $10.69 | -1.11% |
| Week 6 | $6.98 | $8.71 | $10.88 | -1.33% |
| Week 7 | $6.84 | $8.69 | $11.05 | -1.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Adicet Bio, Inc. is a clinical stage biotechnology company that discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Adicet Bio operates in the Healthcare sector, focusing on innovative cellular therapies. Its pipeline includes therapies designed to harness gamma delta T cells for therapeutic applications, with development activities centered in the United States.
These descriptions reflect the company’s stated business focus and location, providing a concise introduction to Adicet Bio and its strategic direction based on the provided facts.
Adicet Bio, Inc. (ACET) is trading at $9.25 per share with a market capitalization of $86.47M and holds a rank of 4284. The stock is positioned within a near-term trading range and sits amidst a backdrop of bullish sentiment according to its technical signals.
The current price and market cap place ACET as a smaller-cap biotechnology stock, with a 30-day price range of $7.31 to $11.70. The current price sits near the middle of that range, reflecting a balance between supply and demand in the short term.
Technical indicators show a bullish tilt in sentiment, with an RSI of 60 and moving averages at SMA50 of $8.15 and SMA200 of $9.02. Support is identified at $7.22 and resistance at $9.31, with annualized volatility at 70% signaling notable price movement potential ahead.
Forecasts for the stock show a path of gradual price evolution over time, with an average price near $9.25 in 2026 and rising to higher levels in later years (for example, a 2030 avg of $13.19 and a 2050 avg of $53.94), accompanied by escalating return expectations.
A major floor 30.8% below — a decisive break under it would weaken the trend.
The nearest floor, 18.2% below — buyers have tended to step in here.
The nearest ceiling, 5.4% above — a clean break opens room to run.
A major ceiling 19.4% above — clearing it would confirm fresh momentum.
Key ACET support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ACET market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.94 | Sell | $8.89 | Sell |
| MA 10 | $8.79 | Buy | $8.75 | Buy |
| MA 20 | $8.40 | Buy | $8.52 | Buy |
| MA 50 | $8.19 | Buy | $8.20 | Buy |
| MA 100 | $7.71 | Buy | $8.18 | Buy |
| MA 200 | $8.98 | Sell | $9.08 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 55.96 | Neutral |
| Stoch RSI (14) | 47.61 | Neutral |
| CCI (20) | 73.31 | Neutral |
| Williams %R (14) | -31.11 | Info |
| MACD (12,26,9) | 0.06 | Buy |
| ROC (12) | 8.34 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 68.89 | Neutral |
| TRIX (15) | 0.34 | Buy |
| Awesome (5,34) | 0.67 | Buy |
| Ultimate (7,14,28) | 55.31 | Neutral |
| Momentum (10) | 0.93 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 9.02 | Sell |
| ADX (14) | 13.62 | Neutral |
| ATR (14) | 0.27 | Info |
Near-term technical picture is bullish overall. The RSI14 at 60 suggests modest upside momentum rather than oversold conditions.
SMA50 at $8.15 and SMA200 at $9.02 place the price above the shorter-term moving average but just below the longer-term baseline, indicating a potential range-bound posture with upside potential. The stock trades within a 30-day range of $7.31 to $11.70, with support at $7.22 and resistance at $9.31.
The combination of bullish sentiment and defined support/resistance levels implies a constructive near-term view, albeit with a near-term range that could see moves toward the resistance around $9.31 or down toward the support near $7.22 depending on market conditions.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.11 | $8.83 | $10.39 | 0% | Neutral | |
| $7.40 | $9.52 | $13.06 | +8% | Neutral | |
| $6.93 | $9.24 | $13.26 | +5% | Neutral | |
| $7.21 | $9.91 | $14.72 | +12% | Neutral | |
| $8.50 | $11.99 | $18.33 | +36% | Bullish | |
| $9.84 | $14.24 | $22.32 | +61% | Bullish | |
| $11.51 | $17.03 | $27.31 | +93% | Bullish | |
| $11.52 | $17.41 | $28.50 | +97% | Bullish | |
| $11.00 | $16.97 | $28.31 | +92% | Bullish | |
| $11.74 | $18.48 | $31.36 | +109% | Bullish | |
| $18.04 | $31.12 | $56.75 | +252% | Bullish | |
| $23.01 | $46.73 | $94.52 | +429% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $6.11 | $8.83 | $10.47 | +0.00% |
| August 2026 | $7.12 | $8.46 | $10.37 | -4.14% |
| September 2026 | $7.15 | $8.58 | $10.66 | +1.32% |
| October 2026 | $7.09 | $8.57 | $10.77 | -0.05% |
| November 2026 | $6.74 | $8.20 | $10.40 | -4.38% |
| December 2026 | $6.64 | $8.12 | $10.39 | -0.94% |
Click any year to see its month-by-month ACET forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ACET price prediction for 2026 points to an average of $8.83 (low $6.11, high $10.39) — a potential gain of 0% on today's $8.83. Price action looks broadly range-bound.
In 2027, ACET is projected to trade between $7.40 and $13.06, averaging $9.52 — a potential gain of +8% from today's $8.83. That is up +8% on the projected 2026 average. A consolidation phase looks the most probable path here.
Adicet Bio, Inc.'s 2028 outlook centres on $9.24, within a $6.93 to $13.26 range. That is -3% versus the projected 2027 average. That marks a +5% change versus current levels. Price action looks broadly range-bound.
By 2029, ACET could reach as high as $14.72, with a base case around $9.91 and support toward $7.21 — roughly +12% from $8.83. A consolidation phase looks the most probable path here.
Expect ACET to range from $8.50 to $18.33 through 2030. The $11.99 average target implies a +36% move from current prices. That is up +21% on the projected 2029 average. Momentum favours further upside here.
The ACET price prediction for 2031 points to an average of $14.24 (low $9.84, high $22.32) — a potential gain of +61% on today's $8.83. Buyers look set to stay in control over this stretch.
In 2032, ACET is projected to trade between $11.51 and $27.31, averaging $17.03 — a potential gain of +93% from today's $8.83. That is up +20% on the projected 2031 average. Momentum favours further upside here.
Adicet Bio, Inc.'s 2033 outlook centres on $17.41, within a $11.52 to $28.50 range. That is up +2% on the projected 2032 average. That marks a +97% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ACET could reach as high as $28.31, with a base case around $16.97 and support toward $11.00 — roughly +92% from $8.83. Momentum favours further upside here.
Expect ACET to range from $11.74 to $31.36 through 2035. The $18.48 average target implies a +109% move from current prices. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ACET price prediction for 2040 points to an average of $31.12 (low $18.04, high $56.75) — a potential gain of +252% on today's $8.83. Momentum favours further upside here.
In 2050, ACET is projected to trade between $23.01 and $94.52, averaging $46.73 — a potential gain of +429% from today's $8.83. That is up +50% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ACET today (≈ 113.250283 ACET) could be worth
$5,291.77
+$4,291.77 (+429%) by 2050 · US Dollar
Based on the average projected ACET price of $46.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ACETwould be worth at today's price.
$1,000 invested in ACET on Jul 10, 2025 (≈ 84.459458 ACET) would be worth
$745.78
-$254.22 (-25.4%) today · 0.75× · US Dollar
Based on a ACET entry price of $11.84 vs. today's $8.83.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9 | $981.11 | -1.9% |
| 1 month ago | $7.31 | $1,207.93 | +20.8% |
| 3 months ago | $6.76 | $1,306.21 | +30.6% |
| 6 months ago | $7.81 | $1,130.6 | +13.1% |
| 1 year ago | $11.84 | $745.78 | -25.4% |
| All time (5.0y) ago | $136 | $64.93 | -93.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ACET forecast.
Our base-case forecast reaches $18.00 around 2035.
Implied market cap at $18.00: $168.27M
The multi-year forecast shows growing upside across the years with a sequence of rising average prices and meaningful ROI improvements. In 2030, the average price is projected at $13.19 with a ROI of 42.6% and a bullish sentiment. By 2040, the average is projected to be $35.49 with a ROI of 283.7% and continued bullish momentum.
By 2050, the average is projected to reach $53.94 with a ROI of 483.2% and a bullish stance remains.
These estimates imply substantial long-term appreciation, but they are not guarantees and depend on a range of factors that can affect performance. The forecasts show a clear path of rising value over time, with higher upside in later years, while acknowledging the inherent uncertainty in future stock movements.
Tap a question to reveal the answer.
Avg $13.19; min $9.26; max $20.37; ROI 42.6%; sentiment BULLISH.
Forecasts indicate a gradual rise from 2026 avg $9.25 (ROI 0%, neutral) to 2030 avg $13.19 (ROI 42.6%, bullish), then to 2040 avg $35.49 (ROI 283.7%, bullish) and 2050 avg $53.94 (ROI 483.2%, bullish). These are estimates, not guarantees.
Yes. The 2030 max price is $20.37.
Current price $9.25; market cap $86.47M.
The 30-day range is $7.31 to $11.70. RSI14 is 60. SMA50 is $8.15 and SMA200 is $9.02. Support is $7.22 and resistance is $9.31.
Adicet Bio, Inc. Community Discussion
0Share your Adicet Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.